Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
HKEX:9926
Akeso, Inc. (9926) Stock Price & Analysis
2 Followers
9926 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$26.45 - HK$60.00
Previous CloseHK$37.75
Volume5.26M
Average Volume (3M)9.73M
Market Cap
HK$33.47B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)13.6
Beta1.27
Next Earnings
Aug 20, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.77
Shares Outstanding865,857,176
10 Day Avg. Volume1,466,300
30 Day Avg. Volume9,727,157
Standard Deviation0.20
R-Squared0.14
Alpha-0.00875
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$58.69Price Target Upside55.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Akeso, Inc. News
PremiumCompany Announcements
Akeso, Inc. Schedules Annual General Meeting
PremiumCompany Announcements
Akeso, Inc. Proposes Share Scheme Overhaul
PremiumCompany Announcements
Akeso Broadens Ivonescimab Agreement With SummitPremiumCompany Announcements
Akeso’s Ivonescimab Outperforms in Clinical TrialBulls Say, Bears Say
Bulls Say
Drug Approval And PerformanceIvonescimab received its first NDA approval in China for EGFRmut nsNSCLC that progressed on EGFR-TKI.
Financial PerformanceAkeso recorded RMB4.53bn in revenue, surpassing the Company’s initial guidance.
Market PotentialAnalyst maintains a BUY rating, recognizing the blockbuster potential of AK104 and AK112, and anticipates strong future sales for cadonilimab.
Bears Say
Clinical TrialsPublished ASCO abstract has seen lower efficacy in Ph III vs previously reported Ph II data.
Market CompetitionInnovent's sintilimab has been approved for the same indication a year ago and has a lead in its market launch.
Market SentimentThe share price fall of c. 40% was triggered by weakened sentiment on the upcoming AK112-303 readout.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.81% Mutual Funds
4.48% Other Institutional Investors
92.72% Public Companies and
Individual Investors
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$26.45 and its highest was HK$60.00 in the past 12 months.
What is Akeso, Inc.’s market cap?
Currently, no data Available
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Aug 20, 2024 which is in 51 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Mar 18, 2024. The company reported -HK$0.64 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.64.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 865,857,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.192%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
---
Akeso, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.05%
12-Months-Change
Fundamentals
Return on Equity
57.08%
Trailing 12-Months
Asset Growth
63.82%
Trailing 12-Months
Company Description
Akeso, Inc.
Akeso Inc is a clinical-stage biopharmaceutical company committed to in-house discovery, development, and commercialization of therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology, and other therapeutic areas. The company's drug candidates include AK104 for recurrent or metastatic cervical cancer, Penpulimab (AK105) for the treatment of patients with classical Hodgkin's lymphoma, AK112 for advanced solid tumors, AK101 for the treatment of ulcerative colitis, AK111 for moderate-to-severe psoriasis, Ebronucimab (AK102) for the treatment of patients with a high or very high risk of hypercholesterolemia, and others.
---
9926 Stock 12 Month Forecast
Average Price Target
HK$58.69
▲(55.47% Upside)
Technical Analysis
Best Analysts Covering 9926
1 Year
---